Please assess the completion status of the following clinical trial:

Trial Title: To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* HS disease duration of at least 3 months before screening.~* Willingness to avoid pregnancy or fathering children.~* Active HS in at least 2 distinct anatomical areas.~* Participants agree NOT to use topical antiseptics on the areas affected by HS lesions during the placebo-controlled 16-week treatment period~Exclusion Criteria:~* Draining fistula count of \> 20 at screening or baseline.~* Women who are pregnant (or who are considering pregnancy) or lactating.~* Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.~* History of failure to treatment of inflammatory diseases with JAK inhibitors.~* Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.~* Participants known to be infected with HIV, Hepatitis B, or Hepatitis C.~* Laboratory values outside of the protocol-defined ranges.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- INCB054707 15 mg (Type: EXPERIMENTAL): Participants will receive INCB054707 15 milligrams (mg) for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.
- INCB054707 45 mg (Type: EXPERIMENTAL): Participants will receive INCB054707 45 mg for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.
- INCB054707 75 mg (Type: EXPERIMENTAL): Participants will receive INCB054707 75 mg for 52 weeks in the Placebo-controlled Treatment Period (16 weeks) plus the Open-label Extension Period (36 weeks). Participants will have the option to continue open-label treatment for an additional 48 weeks.
- Placebo followed by INCB054707 75 mg (Type: PLACEBO_COMPARATOR): Participants will receive placebo for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).